Fig. 1

Flow diagram of the FORTUNE protocol. A total of 41 to 45 patients will be enrolled; it is expected that the number of patients in Group A, B, C, and D will be approximately 10, 15, 15, and 5, respectively. Group A includes patients with advanced solid tumors harboring FGFR1-3 fusion. Group B includes patients with advanced solid tumors harboring FGFR1-3 mutation suggesting that the efficacy of E7090 is promising by MANO method. Group C includes patients with advanced solid tumors harboring FGFR1-3 mutation other than what is included Group B and/or FGFR1, 2 amplification. Group D includes patients with cholangiocarcinoma harboring FGFR2 gene fusion who received prior selective FGFR inhibitors other than E7090. E7090 is administered once daily as an oral single agent in 28-day cycles